Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Multi-Ingredient Supplementation in Professional Football Players (TCP-Soccer)

tiistai 30. kesäkuuta 2026 päivittänyt: Krzysztof Mizera, Vizja University in Warsaw

Dose-Dependent Effects of Multi-Ingredient Supplementation on Physical Performance, Recovery, and Cognitive Function in Professional Football Players

This randomized double-blind placebo-controlled trial will investigate the effects of multi-ingredient supplementation containing taurine, caffeine, and phosphatidylserine on physical performance, cognitive function, cognitive fatigue responses, recovery, sleep quality, and autonomic nervous system activity in elite male soccer players. Participants will complete a 14-day supplementation protocol and undergo football-specific performance, reaction-time, cognitive-fatigue, recovery, and sleep-related assessments before and after the intervention. The study aims to determine whether phosphatidylserine dose influences physical, cognitive, fatigue-related, and recovery-related outcomes when combined with taurine and caffeine.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

The planned study will be a randomized, double-blind, placebo-controlled trial designed as a continuation and extension of previous research on multi-ingredient supplementation in professional football players. The primary aim will be to investigate the dose-dependent effects of phosphatidylserine combined with taurine and caffeine under standardized football-specific training conditions and acute cognitive-fatigue conditions.

Approximately 80 professional male football players competing at national level will be randomly assigned to four groups: placebo, taurine + caffeine, taurine + caffeine + phosphatidylserine 300 mg, and taurine + caffeine + phosphatidylserine 600 mg. Importantly, caffeine and taurine doses will remain identical across all active supplementation groups in order to enable a more precise evaluation of the independent effects of phosphatidylserine.

Participants will complete a 14-day supplementation protocol and undergo baseline and post-intervention assessments including 30 m sprint performance, reaction time, cognitive-fatigue responses, football-specific GPS monitoring, fatigue-related performance decline, recovery-related variables, sleep monitoring, and autonomic nervous system activity assessment.

The study is expected to provide novel insights into the role of phosphatidylserine in football-specific performance, cognitive fatigue resistance, recovery, and neurophysiological responses in elite football players.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

97

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Espanja
      • Alicante, Espanja
        • Professional Football Training Center
  • Puola
      • Lodz, Puola
        • Professional Football Training Center
      • Warsaw, Puola
        • Professional Football Training Center
      • Wroclaw, Puola
        • Professional Football Training Center
  • Unkari
      • Budapest, Unkari
        • Professional Football Training Center

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

-

Inclusion Criteria:

  • Professional male football players aged 18-35 years
  • Regular participation in team training and competitive matches
  • Clinically healthy status confirmed prior to participation
  • Written informed consent provided

Exclusion Criteria:

  • Current musculoskeletal injury or illness
  • Chronic metabolic, cardiovascular, or neurological disease
  • Regular medication use
  • Current use of dietary supplements or ergogenic aids
  • Smoking or excessive alcohol consumption
  • Known hypersensitivity to any study supplement ingredient

Exclusion Criteria:

-

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Muut
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Placebo Comparator: P
Participants will receive visually identical placebo capsules for 14 days.
Muut: Placebo
Placebo capsules administered daily during the 14-day intervention period
Kokeellinen: TC
Participants will receive taurine (1500 mg/day) and caffeine (200 mg/day) supplementation for 14 days.
Ravintolisä: taurine
Taurine supplementation administered daily during the 14-day intervention period.
Ravintolisä: Caffeine
Caffeine supplementation administered daily during the 14-day intervention period.
Kokeellinen: TCP-300
Participants will receive taurine (1500 mg/day), caffeine (200 mg/day), and phosphatidylserine (300 mg/day) supplementation for 14 days.
Ravintolisä: taurine
Taurine supplementation administered daily during the 14-day intervention period.
Ravintolisä: Caffeine
Caffeine supplementation administered daily during the 14-day intervention period.
Ravintolisä: Phosphatidylserine
Phosphatidylserine supplementation administered daily during the 14-day intervention period.
Kokeellinen: TCP-600
Participants will receive taurine (1500 mg/day), caffeine (200 mg/day), and phosphatidylserine (600 mg/day) supplementation for 14 days.
Ravintolisä: taurine
Taurine supplementation administered daily during the 14-day intervention period.
Ravintolisä: Caffeine
Caffeine supplementation administered daily during the 14-day intervention period.
Ravintolisä: Phosphatidylserine
Phosphatidylserine supplementation administered daily during the 14-day intervention period.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
30 m sprint time
Aikaikkuna: Baseline and after 14 days of supplementation

Time required to complete a 30 m sprint, measured using electronic timing gates. The best result from three maximal sprint trials will be used for analysis.

Unit of Measure: seconds
Baseline and after 14 days of supplementation

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Visual reaction time
Aikaikkuna: Baseline and after 14 days of supplementation
Mean response time to a visual stimulus, measured using a validated visual reaction time test.
Baseline and after 14 days of supplementation
Auditory reaction time
Aikaikkuna: Baseline and after 14 days of supplementation
Mean response time to an auditory stimulus, measured using a computerized auditory reaction time test.
Baseline and after 14 days of supplementation
Total distance covered
Aikaikkuna: After 14 days of supplementation, during the standardized football-specific training session

Total distance covered during the standardized football-specific training session, measured using a 10-Hz GPS tracking system. Unit of Measure:

meters
After 14 days of supplementation, during the standardized football-specific training session
Relative distance
Aikaikkuna: After 14 days of supplementation, during the standardized football-specific training session

Distance covered per minute during the standardized football-specific training session, measured using a 10-Hz GPS tracking system. Unit of Measure:

meters per minute
After 14 days of supplementation, during the standardized football-specific training session
High-speed running distance
Aikaikkuna: After 14 days of supplementation, during the standardized football-specific training session

Description:

Distance covered at running speeds above 19.8 km/h during the standardized football-specific training session, measured using a 10-Hz GPS tracking system.

Unit of Measure: meters
After 14 days of supplementation, during the standardized football-specific training session
Number of sprints
Aikaikkuna: After 14 days of supplementation, during the standardized football-specific training session

Total number of sprint efforts performed during the standardized football-specific training session. Sprinting will be defined as running speed above 25.0 km/h and measured using a 10-Hz GPS tracking system.

Unit of Measure: number of sprints
After 14 days of supplementation, during the standardized football-specific training session
Player Load
Aikaikkuna: After 14 days of supplementation, during the standardized football-specific training session

External training load during the standardized football-specific training session, measured using triaxial accelerometry integrated with the GPS tracking system.

Unit of Measure: arbitrary units
After 14 days of supplementation, during the standardized football-specific training session
Heart rate variability RMSSD
Aikaikkuna: Daily during the 14-day supplementation period
Resting heart rate variability assessed in the morning using the root mean square of successive differences between normal heartbeats. HRV will be measured using a heart rate sensor or wearable device under standardized resting conditions. Unit of Measure: milliseconds
Daily during the 14-day supplementation period
Sleep duration
Aikaikkuna: Daily during the 14-day supplementation period
Total sleep duration assessed using wearable sleep monitoring. Unit of Measure: hours
Daily during the 14-day supplementation period
Sleep efficiency
Aikaikkuna: Daily during the 14-day supplementation period

Percentage of time in bed spent asleep, assessed using wearable sleep monitoring.

Unit of Measure: percent
Daily during the 14-day supplementation period
Subjective fatigue
Aikaikkuna: Daily during the 14-day supplementation period
Subjective fatigue assessed using the fatigue item of the Hooper Index questionnaire on a 1-7 scale, where higher values indicate greater fatigue. Unit of Measure: score on a scale
Daily during the 14-day supplementation period
Muscle soreness
Aikaikkuna: Daily during the 14-day supplementation period

Perceived lower-limb muscle soreness assessed using a 0-10 delayed onset muscle soreness scale, where higher values indicate greater soreness.

Unit of Measure: score on a scale
Daily during the 14-day supplementation period
Stroop task reaction time
Aikaikkuna: Baseline and after 14 days of supplementation
Mean response time during a modified computerized Stroop task assessing cognitive fatigue, inhibitory control, sustained attention, and information processing speed. Unit of Measure: seconds
Baseline and after 14 days of supplementation
Stroop task accuracy
Aikaikkuna: Baseline and after 14 days of supplementation
Percentage of correct responses during a modified computerized Stroop task. Unit of Measure: percent
Baseline and after 14 days of supplementation
Stroop task error rate
Aikaikkuna: Baseline and after 14 days of supplementation
Number of incorrect responses during a modified computerized Stroop task. Unit of Measure: number of errors
Baseline and after 14 days of supplementation
Perceived mental fatigue
Aikaikkuna: Baseline and after 14 days of supplementation
Subjective perceived mental fatigue assessed using a 0-10 visual analogue scale, where higher values indicate greater perceived mental fatigue. Unit of Measure: score on a 0-10 scale
Baseline and after 14 days of supplementation
Change in sprint count between first and second half
Aikaikkuna: After 14 days of supplementation, during the standardized football-specific training session

Percentage decline in the number of sprints between the first and second half of the standardized football-specific training session. Sprint change will be calculated as: [(second half value - first half value) / first half value] × 100.

Unit of Measure: percent
After 14 days of supplementation, during the standardized football-specific training session

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Vizja University in Warsaw

Tutkijat

  • Päätutkija: Krzysztof Maciej MIZERA, PhD, 1. Vizja University in Warsaw, Faculty of Medical Sciences and Health Sciences, 01-143 Warsaw, Poland

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Sunnuntai 14. kesäkuuta 2026

Ensisijainen valmistuminen (Todellinen)

Tiistai 30. kesäkuuta 2026

Opintojen valmistuminen (Todellinen)

Tiistai 30. kesäkuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 13. toukokuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Sunnuntai 17. toukokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 22. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 2. heinäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 30. kesäkuuta 2026

Viimeksi vahvistettu

Maanantai 1. kesäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • MIZERA-FOOTBALL-2026

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

IPD-suunnitelman kuvaus

Data sharing plans have not yet been finalized.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa